HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts

Rhea-AI Filing Summary

HUTCHMED (China) Limited has scheduled the announcement of its interim results for the six months ended June 30, 2026 for Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time, 12:00 noon British Summer Time and 7:00 pm Hong Kong Time. Management will host two webcast presentations with Q&A: an English webcast on July 30, 2026 at 8:00 am EDT, 1:00 pm BST and 8:00 pm HKT, and a Putonghua webcast on July 31, 2026 at 8:30 am HKT (1:30 am BST and 8:30 pm EDT on July 30, 2026). The live and replay webcasts and presentation materials will be accessible via the company website. HUTCHMED is described as an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases, with three medicines marketed in China and one also approved in the US, Europe and Japan.

Key Figures

Interim results announcement: July 30, 2026 at 7:00 am EDT English webcast time: July 30, 2026 at 8:00 am EDT Putonghua webcast time: July 31, 2026 at 8:30 am HKT

3 metrics

Interim results announcement July 30, 2026 at 7:00 am EDT Announcement for six months ended June 30, 2026

English webcast time July 30, 2026 at 8:00 am EDT Analyst and investor webcast with Q&A

Putonghua webcast time July 31, 2026 at 8:30 am HKT Chinese-language webcast for interim results

Key Terms

interim results, webcast presentations, commercial-stage, biopharmaceutical company, +2 more

6 terms

interim results financial

"will announce its interim results for the six months ended June 30, 2026"

webcast presentations financial

"HUTCHMED management will host two webcast presentations for analysts and investors"

commercial-stage financial

"HUTCHMED ... is an innovative, commercial-stage, biopharmaceutical company"

A commercial-stage company has moved beyond research and development and is actively selling one or more products or services to customers, generating recurring revenue from the market. For investors, this matters because it shifts the focus from uncertain future milestones to current sales, cash flow and margins—similar to a recipe becoming a working restaurant—reducing some development risk while introducing operational and market risks tied to scaling, competition and customer demand.

biopharmaceutical company financial

"is an innovative, commercial-stage, biopharmaceutical company"

targeted therapies medical

"development and commercialization of targeted therapies and immunotherapies"

Targeted therapies are medicines designed to act on specific molecules or cells that drive a disease, like a guided missile that aims at the bad actors while leaving most healthy tissue alone. For investors, they matter because their precision can lead to stronger results, faster regulatory approval, and premium pricing but also concentrated markets and technical or regulatory risk, so progress in development or clinical tests can quickly change a company’s value.

immunotherapies medical

"development and commercialization of targeted therapies and immunotherapies"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/30/2026 - 06:05 AM Accepted by SEC EDGAR 06/30/2026 - 06:05 AM Learn about SEC filing dates

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of June 2026

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.	​ ​ ​	Description
​	​	​
Exhibit 99.1	​	Announcement relating to notice of announcement of 2026 interim results ​
​	​	​
​	​	​
​	​	​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​	HUTCHMED (CHINA) LIMITED
​	​	​
​	​	​
​	By:	/s/ Johnny Cheng
​	Name:	Johnny Cheng
​	Title:	Chief Financial Officer

​

​

Date: June 30, 2026

3

Exhibit 99.1

​

​

​

HUTCHMED to Announce 2026 Half-Year Financial Results

​
​
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, June 30, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).

​

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, July 30, 2026, at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will be held at 8:30 am HKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30, 2026).

​

Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
​	​
Media Enquiries	​
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
​	​
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
​	​
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
​	​
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

​

FAQ

When will HUTCHMED (HCM) release its 2026 half-year financial results?

HUTCHMED will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time, 12:00 noon British Summer Time and 7:00 pm Hong Kong Time.

What investor webcasts will HUTCHMED (HCM) host for the 2026 interim results?

HUTCHMED will host two webcasts with Q&A. The English webcast is on July 30, 2026 at 8:00 am EDT, 1:00 pm BST, 8:00 pm HKT. The Putonghua webcast is on July 31, 2026 at 8:30 am HKT (1:30 am BST, 8:30 pm EDT on July 30).

How can investors access HUTCHMED’s 2026 interim results presentations?

Both live webcasts and a replay will be available through HUTCHMED’s website at www.hutch-med.com/event/. The related presentation materials will be downloadable shortly before each webcast begins, giving investors direct online access to the results discussion.

What type of company is HUTCHMED (HCM) and what does it focus on?

HUTCHMED is an innovative, commercial-stage biopharmaceutical company. It focuses on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases, with three medicines marketed in China and one also approved in the US, Europe and Japan.

In which markets are HUTCHMED’s approved medicines currently available?

HUTCHMED’s first three medicines are marketed in China, and its first approved medicine is also available internationally, including in the United States, Europe and Japan. This reflects the company’s global development and commercialization efforts for its therapies.

Where can investors and media contact HUTCHMED (HCM) regarding the 2026 interim results?

Investor enquiries can be directed to +852 2121 8200 or ir@hutch-med.com. Media enquiries can go through FTI Consulting and Brunswick via the contacts and phone numbers listed, including HUTCHMED@fticonsulting.com and HUTCHMED@brunswickgroup.com.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 13.3 KB